DOCS

Doximity Inc. Class A Common Stock (DOCS) | Rumor.io

Doximity

DOCS

Attention (50-day avg)0%

Attention rank (50-day avg)#794

Bullish sentiment (50-day avg)64%

Price to earnings ratio31.4

Market capitalization4.7B

Earnings per share0.84

Dividend yield (TTM)—

Revenue (annual)644.9M

Net income (annual)196.1M

Social

What share of all stock conversation is about DOCS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% -0.01	0% +0

Aug 13

Doximity, Inc. ($DOCS) may be experiencing a short squeeze, with some users considering a "dice roll" on the stock.
The stock has established strong support around the $25 level, with some users adding to their positions.
Analysts are split on the stock, but some have raised their price targets, with Truist raising theirs from $19 to $24, and some predicting a price of $30 or more.

Generated by AI

Sentiment

Of the messages about DOCS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +36.6	57.62% -10.67
Bearish	—	—	0% -36.6	42.38% +10.67

Bullish· Aug 7

$DOCS has seen a significant increase in value, with a 170% rise in a single day and a 229% surge in premarket trading after the company raised its revenue forecast and posted impressive sales.
The asset's forward guidance is extremely bullish on AI, which could be a turning point for the company, and the risk-reward is better for the bulls now.
With a large short interest in the name, a squeeze hasn't even started yet, and the price target has been raised to $40 from $22 by Evercore ISI analyst Elizabeth Anderson.

Bearish· Aug 10

The company's recent earnings were considered bad, which may indicate a decline in the stock's value.
The stock is expected to drop below $20, with some predicting it will reach as low as $18.
The stock is likely to continue trading sideways or decline, with some users predicting a gap close in the low 20s.

Generated by AI

Topics

Of the messages about DOCS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Controversies	—	100%	60%	0.17%
Technical Analysis	—	0%	0%	0.92%
Announcements	—	0%	40%	31.26%
Earnings	—	0%	0%	29.78%
Analysts	—	0%	0%	19.73%
Macro	—	0%	0%	18.12%

Earnings· May 14

Doximity (DOCS) shares slumped after a weaker-than-expected full-year forecast, with AI investments pressuring earnings, prompting KeyBanc Capital Markets to cut the stock to sector weight.
Doximity missed earnings expectations and lowered guidance, leading to a 24% price drop and raising concerns about the company's bottom-line earnings miss and sharply lowered forward guidance.
Doximity's Q4 2026 earnings report showed a 4% revenue growth forecast for fiscal 2027, amid soft pharmaceutical ad spending, and management's cautious revenue guide led to a repricing of growth and margin expansion expectations.

Analysts· May 18

Analysts have lowered their price targets for Doximity (DOCS) stock, with SVB Securities reducing its target to $67 and Baird lowering its target to $45.
Jefferies Financial Group has maintained its Buy rating for DOCS with a price target of $46, while Guggenheim has maintained its Buy rating with a price target of $52.
Doximity's recent stock price decline is seen as a buying opportunity by Guggenheim analysts, who believe the company's growth prospects remain strong despite the multiple compression.

Announcements· Aug 4

Doximity, Inc. (DOCS) reported FY23Q1 financial results, with non-GAAP EPS of $0.14 vs $0.1 (estimated) and revenue of $90.6M vs $89.3M (estimated), representing a 25% YoY growth in revenue.
Doximity has appointed Phoebe Yang to its Board of Directors, bringing her expertise in healthcare and technology to the company.
Doximity has launched its Environmental, Social and Governance (ESG) website, highlighting its commitment to corporate social responsibility and transparency in its operations.

Technical Analysis· Aug 23

$DOCS has been trading at all-time highs and has shown strong price and volume action, with a 10d MA bounce and two distinct pullback zones.
The stock has a solid momentum, with a straight up 12% move from entry, and has formed a bull flag on low volume that has held up well above the 10EMA and AVWAP.
The stock is showing a perfect buy point where it tested the 8 EMA and the old resistance line for new support, and has a target of $85 with a risk of stopping under $70.

Generated by AI

Community

Of the messages about DOCS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	98.26%	27.82%
Newcomers	—	100%	1.74%	72.18%

Regulars· Aug 7

Doximity shares surged 229% in premarket trading after the company raised its revenue forecast for fiscal 2027 and posted sales ahead of expectations.
Evercore ISI raised Doximity's price target to $40 from $22, citing the company's momentum in AI search and its potential for better revenue growth.
Morgan Stanley noted that Doximity's AI search momentum is building faster than expected, with the firm maintaining an Overweight rating and $35 price target on the shares.

Newcomers· Aug 11

Newcomers are focused on the potential for DOCT's price to drop further, with some mentioning a specific price level ($28) as a potential turning point.
There is a debate about the sustainability of DOCT's price, with some users questioning whether the company will be able to hold onto its current value ("those bags").
Some newcomers are optimistic about DOCT's potential for growth, with a few users suggesting specific price targets ($26, $27.40) or calling for a price increase ("get over $26", "Lets go").

Generated by AI

News

Kaplan Fox Encourages Doximity, Inc. (NYSE: DOCS) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 16, 2026

NewMediaWire Press Release.

14h agoThe Globe and Mail

Doximity (DOCS) Gains As Market Dips: What You Should Know

In the latest trading session, Doximity (DOCS) closed at $26.52, marking a +1.22% move from the previous day.

14h agoYahoo Finance Singapore

Doximity, Inc. (DOCS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

17h agoMorningstar

Kaplan Fox Encourages Investors of Doximity, Inc. (NYSE: DOCS) to Contact the Firm Before Lead Plaintiff Deadline on November 16, 2026

4d agoBarchart.com

DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

5d agoMorningstar

What Doximity (DOCS)'s Bedside Bench AI Benchmark Launch Means For Shareholders

7d agoYahoo Finance

Also Discussed

Investors talking about DOCS also mention

#	Name	Attention
1	Global-E Online Ltd.GLBE	0%new
2	dLocal LimitedDLO	0%new
3	CFLT - Confluent, Inc.	——
4	Teladoc Health Inc.TDOC	0%+0
5	OptimizeRx CorporationOPRX	0%0
6	ZoomInfo Technologies Inc.GTM	0%0
7	American Well Corporation Class A Common StockAMWL	0%+0
8	Upstart Holdings, Inc.UPST	0.01%0
9	Asana Inc. Class A Common StockASAN	0%new
10	TaskUs, Inc. Class A Common StockTASK	0%new

Doximity Inc. Class A Common Stock

Healthcare
Health Information Services

Doximity Inc. Class A Common Stock represents ownership in Doximity, a U.S.-based digital platform built for medical professionals. Doximity provides cloud-based tools that help physicians, nurse practitioners, physician assistants, and medical students collaborate with colleagues, coordinate patient care, conduct virtual patient visits, access curated medical news and research, and manage careers and on-call schedules. The company focuses on healthcare communications and workflow software, serving the medical community through features designed for secure networking, telehealth support, and professional productivity. Doximity plays a notable role in the health information services market by connecting clinicians with tools that support day-to-day clinical coordination and access to specialty-specific information.

Website

Location

500 3rd Street

San Francisco, CA, 94107

United States

Social

What share of all stock conversation is about DOCS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% -0.01	0% +0

Aug 13

Doximity, Inc. ($DOCS) may be experiencing a short squeeze, with some users considering a "dice roll" on the stock.
The stock has established strong support around the $25 level, with some users adding to their positions.
Analysts are split on the stock, but some have raised their price targets, with Truist raising theirs from $19 to $24, and some predicting a price of $30 or more.

Generated by AI

Sentiment

Of the messages about DOCS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +36.6	57.62% -10.67
Bearish	—	—	0% -36.6	42.38% +10.67

Bullish· Aug 7

$DOCS has seen a significant increase in value, with a 170% rise in a single day and a 229% surge in premarket trading after the company raised its revenue forecast and posted impressive sales.
The asset's forward guidance is extremely bullish on AI, which could be a turning point for the company, and the risk-reward is better for the bulls now.
With a large short interest in the name, a squeeze hasn't even started yet, and the price target has been raised to $40 from $22 by Evercore ISI analyst Elizabeth Anderson.

Bearish· Aug 10

The company's recent earnings were considered bad, which may indicate a decline in the stock's value.
The stock is expected to drop below $20, with some predicting it will reach as low as $18.
The stock is likely to continue trading sideways or decline, with some users predicting a gap close in the low 20s.

Generated by AI

Topics

Of the messages about DOCS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Controversies	—	100%	60%	0.17%
Technical Analysis	—	0%	0%	0.92%
Announcements	—	0%	40%	31.26%
Earnings	—	0%	0%	29.78%
Analysts	—	0%	0%	19.73%
Macro	—	0%	0%	18.12%

Earnings· May 14

Doximity (DOCS) shares slumped after a weaker-than-expected full-year forecast, with AI investments pressuring earnings, prompting KeyBanc Capital Markets to cut the stock to sector weight.
Doximity missed earnings expectations and lowered guidance, leading to a 24% price drop and raising concerns about the company's bottom-line earnings miss and sharply lowered forward guidance.
Doximity's Q4 2026 earnings report showed a 4% revenue growth forecast for fiscal 2027, amid soft pharmaceutical ad spending, and management's cautious revenue guide led to a repricing of growth and margin expansion expectations.

Analysts· May 18

Analysts have lowered their price targets for Doximity (DOCS) stock, with SVB Securities reducing its target to $67 and Baird lowering its target to $45.
Jefferies Financial Group has maintained its Buy rating for DOCS with a price target of $46, while Guggenheim has maintained its Buy rating with a price target of $52.
Doximity's recent stock price decline is seen as a buying opportunity by Guggenheim analysts, who believe the company's growth prospects remain strong despite the multiple compression.

Announcements· Aug 4

Doximity, Inc. (DOCS) reported FY23Q1 financial results, with non-GAAP EPS of $0.14 vs $0.1 (estimated) and revenue of $90.6M vs $89.3M (estimated), representing a 25% YoY growth in revenue.
Doximity has appointed Phoebe Yang to its Board of Directors, bringing her expertise in healthcare and technology to the company.
Doximity has launched its Environmental, Social and Governance (ESG) website, highlighting its commitment to corporate social responsibility and transparency in its operations.

Technical Analysis· Aug 23

$DOCS has been trading at all-time highs and has shown strong price and volume action, with a 10d MA bounce and two distinct pullback zones.
The stock has a solid momentum, with a straight up 12% move from entry, and has formed a bull flag on low volume that has held up well above the 10EMA and AVWAP.
The stock is showing a perfect buy point where it tested the 8 EMA and the old resistance line for new support, and has a target of $85 with a risk of stopping under $70.

Generated by AI

Community

Of the messages about DOCS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	98.26%	27.82%
Newcomers	—	100%	1.74%	72.18%

Regulars· Aug 7

Doximity shares surged 229% in premarket trading after the company raised its revenue forecast for fiscal 2027 and posted sales ahead of expectations.
Evercore ISI raised Doximity's price target to $40 from $22, citing the company's momentum in AI search and its potential for better revenue growth.
Morgan Stanley noted that Doximity's AI search momentum is building faster than expected, with the firm maintaining an Overweight rating and $35 price target on the shares.

Newcomers· Aug 11

Newcomers are focused on the potential for DOCT's price to drop further, with some mentioning a specific price level ($28) as a potential turning point.
There is a debate about the sustainability of DOCT's price, with some users questioning whether the company will be able to hold onto its current value ("those bags").
Some newcomers are optimistic about DOCT's potential for growth, with a few users suggesting specific price targets ($26, $27.40) or calling for a price increase ("get over $26", "Lets go").

Generated by AI

Doximity

Social

Aug 13

Bullish· Aug 7

Bearish· Aug 10

Earnings· May 14

Analysts· May 18

Announcements· Aug 4

Technical Analysis· Aug 23

Regulars· Aug 7

Newcomers· Aug 11

Kaplan Fox Encourages Doximity, Inc. (NYSE: DOCS) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 16, 2026

Doximity (DOCS) Gains As Market Dips: What You Should Know

Doximity, Inc. (DOCS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Kaplan Fox Encourages Investors of Doximity, Inc. (NYSE: DOCS) to Contact the Firm Before Lead Plaintiff Deadline on November 16, 2026

DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

What Doximity (DOCS)'s Bedside Bench AI Benchmark Launch Means For Shareholders

Also Discussed

Doximity Inc. Class A Common Stock

Company Information

Location

Kaplan Fox Encourages Doximity, Inc. (NYSE: DOCS) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 16, 2026

Doximity (DOCS) Gains As Market Dips: What You Should Know

Doximity, Inc. (DOCS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Kaplan Fox Encourages Investors of Doximity, Inc. (NYSE: DOCS) to Contact the Firm Before Lead Plaintiff Deadline on November 16, 2026

DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

What Doximity (DOCS)'s Bedside Bench AI Benchmark Launch Means For Shareholders

Also Discussed

Social

Aug 13

Bullish· Aug 7

Bearish· Aug 10

Earnings· May 14

Analysts· May 18

Announcements· Aug 4

Technical Analysis· Aug 23

Regulars· Aug 7

Newcomers· Aug 11